Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-25 · accession 0001593968-24-000196 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-31 | 2024-01-25 | ALLO | Douglas Earl Martin | SVP, GC | A - Grant | $0.00 | +41.8K | 477.6K | +10% | $0 |
| D | 2024-01-31 | 2024-01-25 | ALLO | Douglas Earl Martin | SVP, GC | A - Grant | $0.00 | +147.8K | 147.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-25 | A | A | 41,800 | $0.00 | 477,634 | D | — | — | |
| 2 | Derivative | Stock Option (Right to buy) | 2024-01-25 | A | A | 147,778 | $0.00 | 147,778 | D | $3.20 · — to 2034-01-25 | 147,778 Common Stock | (F1) 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter. |